Welcome to our dedicated page for KAMADA SEC filings (Ticker: KMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
Kamada Ltd. announced it will hold its Annual General Meeting of Shareholders on December 10, 2025 at 4:00 p.m. Israel time at the company’s offices, 2 Holzman Street, Weizmann Science Park, Rehovot, Israel.
The report states that the Notice and Proxy Statement and the proxy card are attached as Exhibits 99.1 and 99.2 and incorporated by reference. The Form 6-K is also incorporated by reference into Kamada’s Form S-8 registration statements (File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267, 333-265866).
Kamada Ltd. submitted a report as a foreign private issuer stating that it files its annual reports on Form 20-F. The report is being incorporated by reference into several existing Form S-8 registration statements. It also attaches an exhibit announcing Kamada’s participation in upcoming September investor conferences.
Kamada Ltd (KMDA) reported stronger operating results in a Form 6-K filing that includes a company presentation and unaudited consolidated financial statements as of June 30, 2025. The company disclosed 11% year-over-year top-line growth for the first six months and a 35% increase in profitability over the same period. Management also raised full-year profitability guidance. The filing attaches the presentation and the Inline XBRL financial documents for more detail.
Kamada Ltd. reports that the U.S. Food and Drug Administration has approved its plasma collection center in Houston, Texas. This information is provided through a Form 6-K submission that incorporates the report by reference into several existing Form S-8 registration statements. The FDA approval of the Houston plasma collection center represents a regulatory milestone for Kamada’s plasma-related activities in the United States.